2Korytkowski M, Thomas A , Reid L, et al. Glimepiride improves both ftrs andsecond phases of insulin secretion in type 2 diabetes. Diabetes Care 2002 ;25 : 1607 - 1611.
3Rosenstock J, Dailey G, Massi - Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta - analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005 ;28:950 -995.
4Riddle MC, RosenstockJ, Gerich J, et al. The treat - to - target trail: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 ; 26 : 3080 - 3086.
同被引文献31
1UKPDS Study Group. Stratton IM,Adler AI,Neil HAW,Matthews DR, Manley SE,Cull CA,Hadden D,Tumer RC,Holman RR.Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes.prospective observational study(UKPDS 35) Ill. BMJ,2000,321 (12) :405-412.
2Monnier L, Lapinsbi H, Coletle C, et al. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients : variations with increas- ing levels of HbAlc[ J]. Diabetes Care,2003,26(3 ) :881-885.
